Sort by
Refine Your Search
-
application of conditional diffusion models, flow matching techniques, or related generative approaches, as well as experience working with probabilistic (Bayesian) methods and statistical modelling. Strong
-
methodology, theory, and applications across the areas of Bayesian experimental design, active learning, probabilistic deep learning, and related topics. The £1.23M project is funded by the UKRI Horizon
-
use computational approaches to mine natural biodiversity in gene sequences to identify engineering targets to increase lipid content and enhance the water use efficiency. The project will make use
-
their target antigens and become activated in serious human diseases, including autoimmune disorders, infectious diseases, and cancers. We study how adaptive T cell immunity is developed and/or becomes impaired
-
to the development and implementation of strategies/action plans (and ongoing review) to ensure that targets are met according to study timelines. Supervision would be provided by senior Centre staff, including
-
world-leading researchers from Oxford, Harvard, and other premier institutions to develop innovative gene-silencing and gene-editing technologies targeting the underlying causes of genetic heart diseases
-
characterising binding interactions. You will drive the completion of several mature projects to publication, including revealing new roles for disordered domains in efficient DNA target search. You may also
-
in preventing immune-mediated pathology in autoimmunity remains poorly understood. Using genetic and antibody-based targeting, we aim to dissect how these pathways modulate T-cell signalling
-
into disease progression, with the ultimate aim of identifying novel biomarkers and therapeutic targets. You will hold a relevant PhD/DPhil, together with sufficient specialist knowledge in normal and malignant
-
precancers and developing targeted interventions, including vaccines, to intercept them. The project focuses on designing, validating, and preclinically testing neoepitope-based mRNA vaccines to prevent BRCA